3 results
Approved WMOCompleted
Primary: progression-free survival in the GSK1120212-group in comparison with the docetaxel group. Secondary: safety and tolerability, response rate, duration of response, overall survival, PK.
Approved WMORecruiting
To evaluate the safety and efficacy of 177Lu-PSMA RLT in patients with R/M ACC and SDC with PSMA ligand uptake.
Approved WMOCompleted
To demonstrate that Nanocort is safe and effectively reduces the inflammatory signs and symptoms of active GO.